Cargando…
Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) currently lacks a robust and well-defined biomarker that can 1) assess the progression of the disease, 2) predict and/or delineate the various clinical subtypes, and 3) evaluate or predict a patient’s response to treatments. The kynurenine Pathway (KP) of tryptoph...
Autores principales: | Tan, Vanessa X., Guillemin, Gilles J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764462/ https://www.ncbi.nlm.nih.gov/pubmed/31616242 http://dx.doi.org/10.3389/fnins.2019.01013 |
Ejemplares similares
-
Kynurenine and Tetrahydrobiopterin Pathways Crosstalk in Pain Hypersensitivity
por: Staats Pires, Ananda, et al.
Publicado: (2020) -
The Potential for Transition Metal-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis
por: Lovejoy, David B., et al.
Publicado: (2014) -
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
por: Chen, Yiquan, et al.
Publicado: (2009) -
Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis
por: Alarcan, Hugo, et al.
Publicado: (2021) -
Kynurenine, Tetrahydrobiopterin, and Cytokine Inflammatory Biomarkers in Individuals Affected by Diabetic Neuropathic Pain
por: Staats Pires, Ananda, et al.
Publicado: (2020)